Enzon Pharmaceuticals, Inc., a biotechnology company, engages in the research and development of therapeutics for cancer patients with unmet medical needs. The company's drug-development programs utilize two platforms-Customized PEGylation Linker Technology and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. It currently holds four compounds in clinical development and multiple novel LNA targets in preclinical research. The company's development product pipeline consists of PEG-SN38 compound that utilizes Customized Linker Technology, which is in Phase II clinical trials for the treatment of metastatic colorectal and breast cancer, as well as a Phase I trial for pediatric patients with cancer; and the Hypoxia-Inducible Factor-1 alpha antagonist in Phase I studies for the treatment of solid tumors and lymphoma. Its product line also comprises Survivin antagonist in Phase I study in pediatric patients with recurrent acute lymphoblastic leukemia; Androgen Receptor antagonist, a validated target for the treatment of prostate cancer that is in a Phase I study in patients with castration-resistant prostate cancer; and rights to five compounds, including AR, HER3, beta-catenin, PI3KCA, and Gli2. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Piscataway, New Jersey.